PILA PHARMA Advances Proof-of-Concept Study for Rare Pain Disorder Erythromelalgia
Key Insights
PILA PHARMA (search) is preparing a clinical proof-of-concept trial for XEN-D0501, an oral TRPV1 (search) inhibitor, to treat erythromelalgia (search), a rare and debilitating pain disorder with no approved treatments.
The company received FDA orphan drug designation in 2022, providing seven years of market exclusivity and development incentives, with potential for similar EMA designation offering ten years of EU exclusivity.
The development timeline is estimated at three years to market registration, with potential annual sales exceeding SEK 3 billion according to analyst projections.
PILA PHARMA (search) announced preparations for a clinical proof-of-concept study to evaluate XEN-D0501, an oral TRPV1 (search) inhibitor, as a potential treatment for erythromelalgia (search), a rare and extremely debilitating pain disorder that currently has no approved therapeutic options.
Orphan Drug Designation Provides Regulatory Advantages
The Swedish biotech company secured FDA orphan drug designation for erythromelalgia (search) in 2022, providing significant regulatory incentives including shorter development timelines, reduced costs, and seven years of market exclusivity following potential approval. PILA PHARMA (search) expects to receive similar designation from the European Medicines Agency (EMA), which would grant ten years of market exclusivity in the EU.
The company's development strategy involves conducting a smaller proof-of-concept study first to demonstrate XEN-D0501's potential efficacy in relieving perceived pain in erythromelalgia (search) patients, followed by a Phase 2/3 registration trial. PILA PHARMA (search) estimates approximately three years to complete studies up to registration, contingent on securing necessary funding.
Addressing Significant Unmet Medical Need
Erythromelalgia (search) is characterized by burning pain and redness in the extremities, with neurogenic inflammation playing a role in symptom development. The condition can cause near-constant or episodic pain ranging from mild tingling to severe burning sensations, most commonly affecting the feet but potentially occurring in hands, face, or other body parts. The disorder can be extremely debilitating with significant negative impact on quality of life and potential to impact mortality rates among young people and suicide rates among adults.
Symptoms are currently managed primarily through avoidance of pain triggers, leaving patients with limited meaningful treatment options. The Swedish research firm Analyst Group estimated that erythromelalgia (search) could potentially achieve annual sales exceeding SEK 3 billion, reflecting the significant market opportunity for an effective treatment.
TRPV1 Inhibition as Novel Pain Management Approach
XEN-D0501 works by inhibiting the TRPV1 (search) receptor, which plays a key role in regulating pain and inflammation. This receptor has been extensively studied in developing new, non-addictive pain treatments as alternatives to opioids, providing strong scientific rationale for PILA PHARMA (search)'s approach. Persistence Research estimates the market for opioid painkillers amounted to approximately USD 45 billion in 2025 and is expected to grow to USD 62 billion by 2032, representing a significant opportunity for safer pain management alternatives.
The oral tablet formulation offers practical advantages for patients experiencing attacks, allowing for fast and easy administration. With systemic absorption, the drug rapidly distributes to feet and other affected body areas. The treatment could potentially be used both for acute symptom relief and preventive therapy to reduce attack frequency.
Expert Perspectives on Development Program
Founder and Chief Scientific Officer Dorte X. Gram emphasized the patient impact: "Patients often contact me because they have heard about PILA's ambitions to develop an effective treatment that can ease their daily suffering. Based on my conversations with them, they currently have no meaningful treatment options. If XEN-D0501 proves effective in relieving pain without excessive safety concerns, it would truly be a game changer for them and enable them to resume a normal life without the almost constant pain."
Hans Quiding, PILA PHARMA (search)'s scientific expert in pain management with extensive TRPV1 (search) inhibitor experience at AstraZeneca, added: "I have worked extensively with TRPV1 inhibitors in pain management for many years at AstraZeneca, and I am very hopeful that this molecule, with its unique safety profile, could be of great value to EM patients."
Broader Development Portfolio
Beyond erythromelalgia (search), PILA PHARMA (search) has completed two Phase 2a clinical trials (PP-CT01 and PP-CT02) demonstrating that XEN-D0501 is well tolerated in people living with obesity (search) and type 2 diabetes (search). In PP-CT02, XEN-D0501 administered as 4 mg twice daily for 28 days showed statistically significant enhancement of endogenous insulin response to oral glucose versus placebo, with highly significant reduction in ANP, a cardiovascular biomarker for heart failure.
The company reported excellent tolerability following 13 weeks of high-dose administration in two animal species during 2023, supporting progression into longer clinical trials. PILA PHARMA (search) plans to submit a clinical trial application for a dose-finding study in obesity (search) around the end of Q1 2026.